Css LLC Il Reduces Stake in Cencora, Inc. (NYSE:COR)

CSS LLC IL lessened its position in Cencora, Inc. (NYSE:COR - Free Report) by 65.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,238 shares of the company's stock after selling 2,350 shares during the period. CSS LLC IL's holdings in Cencora were worth $278,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of COR. UMB Bank n.a. boosted its position in shares of Cencora by 10.6% in the 4th quarter. UMB Bank n.a. now owns 1,248 shares of the company's stock worth $280,000 after purchasing an additional 120 shares in the last quarter. Simon Quick Advisors LLC bought a new stake in Cencora during the 4th quarter valued at about $211,000. Baker Ellis Asset Management LLC increased its stake in Cencora by 9.6% during the 4th quarter. Baker Ellis Asset Management LLC now owns 2,280 shares of the company's stock valued at $512,000 after purchasing an additional 200 shares in the last quarter. SG Americas Securities LLC raised its holdings in Cencora by 90.2% in the fourth quarter. SG Americas Securities LLC now owns 79,413 shares of the company's stock worth $17,843,000 after buying an additional 37,651 shares during the last quarter. Finally, Bartlett & CO. Wealth Management LLC lifted its stake in shares of Cencora by 2.1% in the fourth quarter. Bartlett & CO. Wealth Management LLC now owns 4,826 shares of the company's stock worth $1,084,000 after buying an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Cencora Stock Performance

Cencora stock traded down $1.68 during midday trading on Wednesday, hitting $291.71. The stock had a trading volume of 247,078 shares, compared to its average volume of 1,539,973. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $309.35. The company has a market capitalization of $56.54 billion, a PE ratio of 41.47, a P/E/G ratio of 1.31 and a beta of 0.60. The firm's fifty day moving average is $283.45 and its two-hundred day moving average is $257.75. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. The firm had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company posted $3.80 earnings per share. On average, research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 2nd. Investors of record on Friday, May 16th will be paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.75%. The ex-dividend date of this dividend is Friday, May 16th. Cencora's dividend payout ratio (DPR) is presently 25.52%.

Wall Street Analysts Forecast Growth

COR has been the subject of several analyst reports. Evercore ISI raised their price target on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Wells Fargo & Company increased their price objective on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research report on Friday, March 14th. Citigroup boosted their target price on Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Bank of America upped their target price on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Finally, Morgan Stanley set a $288.00 price target on shares of Cencora in a research note on Tuesday, April 15th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $301.18.

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 4,969 shares of the business's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the sale, the chief executive officer now directly owns 47,582 shares in the company, valued at approximately $13,766,900.06. The trade was a 9.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total value of $4,108,507.99. Following the transaction, the chairman now directly owns 315,913 shares of the company's stock, valued at approximately $89,027,442.53. The trade was a 4.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 45,223 shares of company stock valued at $12,369,767. Corporate insiders own 10.80% of the company's stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.